|
|
||||||||
i-Independent Signaling and Actin Responses in Human Intestinal Myofibroblasts1


* Department of Pharmacy and Pharmacology, University of Bath, Bath and North East Somerset, United Kingdom;
Division of Immunology, Infection and Inflammation, Western Infirmary, University of Glasgow, Glasgow, United Kingdom; and
Department of Gastroenterology, Faculty of Medicine, University of Crete, Crete, Greece
Intestinal myofibroblasts have been implicated in the pathogenesis of chronic inflammatory conditions such as Crohns disease via interactions with an elaborate network of cytokines, growth factors, and other inflammatory mediators. CXCR3 is a G
i protein-coupled receptor that binds the proinflammatory chemokines CXCL9, CXCL10, and CXCL11, which are released from the intestinal epithelium. The three CXCR3 ligands shared the ability to activate biochemical (e.g., PI3K and MAPK activation) and functional events (actin reorganization) in intestinal myofibroblasts. However, CXCL11 is unique in its ability to elevate intracellular calcium. Surprisingly, although CXCR3 mRNA is detectable in these myofibroblasts, there is no detectable surface expression of CXCR3. Furthermore, the biochemical responses and actin reorganization stimulated by the CXCR3 ligands in intestinal myofibroblasts are insensitive to the G
i inhibitor, pertussis toxin. This suggests either the existence of differential receptor coupling mechanisms in myofibroblasts for CXCR3 that are distinct from those observed in PBLs and/or that these cells express a modified or variant CXCR3 compared with the CXCR3 expressed on PBLs.
This article has been cited by other articles:
![]() |
R. J. Bodnar, C. C. Yates, M. E. Rodgers, X. Du, and A. Wells IP-10 induces dissociation of newly formed blood vessels J. Cell Sci., June 15, 2009; 122(12): 2064 - 2077. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Okamura, S. Pennathur, K. Pasichnyk, J. M. Lopez-Guisa, S. Collins, M. Febbraio, J. Heinecke, and A. A. Eddy CD36 Regulates Oxidative Stress and Inflammation in Hypercholesterolemic CKD J. Am. Soc. Nephrol., March 1, 2009; 20(3): 495 - 505. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Datta, A. G. Contreras, M. Grimm, A. M. Waaga-Gasser, D. M. Briscoe, and S. Pal Calcineurin Inhibitors Modulate CXCR3 Splice Variant Expression and Mediate Renal Cancer Progression J. Am. Soc. Nephrol., December 1, 2008; 19(12): 2437 - 2446. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Datta, J. A. Flaxenburg, S. Laxmanan, C. Geehan, M. Grimm, A. M. Waaga-Gasser, D. M. Briscoe, and S. Pal Ras-induced Modulation of CXCL10 and Its Receptor Splice Variant CXCR3-B in MDA-MB-435 and MCF-7 Cells: Relevance for the Development of Human Breast Cancer Cancer Res., October 1, 2006; 66(19): 9509 - 9518. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Rahangdale, R. Morgan, C. Heijens, T. C. Ryan, H. Yamasaki, E. Bentley, E. Sullivan, D. M. Center, and W. W. Cruikshank Chemokine Receptor CXCR3 Desensitization by IL-16/CD4 Signaling Is Dependent on CCR5 and Intact Membrane Cholesterol J. Immunol., February 15, 2006; 176(4): 2337 - 2345. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |